About aquestive therapeutics inc - AQST
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
AQST At a Glance
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, New Jersey 07059
| Phone | 1-908-941-1900 | Revenue | 57.56M | |
| Industry | Pharmaceuticals: Major | Net Income | -44,137,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 13.795% | |
| Fiscal Year-end | 12 / 2025 | Employees | 142 | |
| View SEC Filings |
AQST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.364 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.95 |
| Enterprise Value to Sales | 6.239 |
| Total Debt to Enterprise Value | 0.34 |
AQST Efficiency
| Revenue/Employee | 405,359.155 |
| Income Per Employee | -310,823.944 |
| Receivables Turnover | 7.838 |
| Total Asset Turnover | 0.725 |
AQST Liquidity
| Current Ratio | 4.676 |
| Quick Ratio | 4.356 |
| Cash Ratio | 3.793 |
AQST Profitability
| Gross Margin | 68.951 |
| Operating Margin | -53.458 |
| Pretax Margin | -76.703 |
| Net Margin | -76.679 |
| Return on Assets | -55.573 |
| Return on Equity | N/A |
| Return on Total Capital | -71.44 |
| Return on Invested Capital | -176.03 |
AQST Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 197.368 |
| Total Debt to Total Assets | 120.226 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 194.741 |